Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia.

Acute erythroleukemia (AEL) is an infrequent subtype of acute myeloid leukemia (AML) with worse prognosis. Though the last decade has seen major advances in the novel features and genomic landscape in AEL, there is still a lack of specific therapeutic targets and effective treatment approaches for this disease. Here, we found a novel oncogene KEL that specifically and aberrantly expressed in patients with AEL. In this study, we demonstrated that KEL promoted cell proliferation and the downregulation of KEL reversed drug resistance in AEL cells to JQ1. Our findings suggested that KEL contributed to gain of H3K27 acetylation and promoted erythroid differentiation induced by GATA1. Additionally, GATA1 and TAL1 as cotranscription factors (TFs) modulated the expression of KEL. Maintaining cell viability and differentiation, KEL also played parts in the immune evasion of tumor cells. Our work expands the current knowledge regarding molecular mechanisms involved in cancer onset and progression, offering promising therapeutic target to broaden the treatment options. Copyright © 2022 Wenjie Liu et al.

Citation

Wenjie Liu, Zijuan Wu, Yan Yu, Chun Qiao, Han Zhu, Ming Hong, Yu Zhu, Sixuan Qian, Suning Chen, Depei Wu, Jianyong Li, Hui Jin. Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia. Oxidative medicine and cellular longevity. 2022;2022:5885342

Mesh Tags

Substances

PMID: 35140839

search → result